SCUELJapan healthcare data

Home › Japan pharmaceutical market › Angiotensin II receptor blockers (ARBs)

Japan market size · Drug class

Angiotensin II receptor blockers (ARBs) in Japan

ARB（アンジオテンシンII受容体拮抗薬）

The prescription value of Angiotensin II receptor blockers (ARBs) (7 molecules) in Japan was an estimated ¥77.5 billion in FY2024. Value changed -35.0% year on year and -26.7% a year on average over the last three years. The largest molecule is Azilsartan (32%). In addition, 13 combination products totalled ¥49.5 billion.

¥77.5bnValue FY2024 (single agents)
-35.0%Year on year
-26.7%3-year average growth

Trend and molecules

Hover or tap a year for the values.

Trend (single agents)

Prescription value (est.)YoY upYoY down

By molecule (FY2021 = 100)

Molecules in this class

AzilsartanアジルサルタンオルメサルタンメドキソミルオルメサルタンメドキソミルカンデサルタンシレキセチルカンデサルタンシレキセチルTelmisartanテルミサルタンValsartanバルサルタンLosartan PotassiumロサルタンカリウムIrbesartanイルベサルタンAzilsartan / Amlodipine Besilateアジルサルタン・アムロジピンベシル酸塩Telmisartan / Amlodipine Besilateテルミサルタン・アムロジピンベシル酸塩Irbesartan / Amlodipine Besilateイルベサルタン・アムロジピンベシル酸塩カンデサルタンシレキセチル・アムロジピンベシル酸塩カンデサルタンシレキセチル・アムロジピンベシル酸塩オルメサルタンメドキソミル・アゼルニジピンオルメサルタンメドキソミル・アゼルニジピンValsartan / Amlodipine Besilateバルサルタン・アムロジピンベシル酸塩Losartan Potassium / Hydrochlorothiazideロサルタンカリウム・ヒドロクロロチアジドTelmisartan / Hydrochlorothiazideテルミサルタン・ヒドロクロロチアジドカンデサルタンシレキセチル・ヒドロクロロチアジドカンデサルタンシレキセチル・ヒドロクロロチアジドValsartan / Hydrochlorothiazideバルサルタン・ヒドロクロロチアジドValsartan / Cilnidipineバルサルタン・シルニジピンIrbesartan / Trichlormethiazideイルベサルタン・トリクロルメチアジドTelmisartan / Amlodipine Besilate / Hydrochlorothiazideテルミサルタン・アムロジピンベシル酸塩・ヒドロクロロチアジド
All markets

Need the numbers behind the lines?

Year-by-year values for each related drug, company-level shares, and Excel downloads are available to our clients in Japan. Tell us what you are looking at and we will reply in English.

Contact us

About the data

Values are estimates: prescription volumes from Japan's NDB Open Data (Ministry of Health, Labour and Welfare; excluding public-expense claims), FY2015–FY2024, multiplied by the NHI reimbursement price of each product at the time of each release (nominal). All strengths and brands of the molecule are combined. Japanese fiscal years run from April to March (FY2024 = April 2024 – March 2025). Until FY2023 the NDB lists only the top products by volume in each therapeutic class; years in which a molecule is not listed are shown as “not listed”. Growth rates compare the same products in consecutive years and are chained; the 3-year rate is not shown when the base year value is below one tenth of the latest year. The comparison with related drugs is an index with FY2021 = 100. Supply: MHLW, as of 2026-09-27.